<DOC>
	<DOC>NCT00492388</DOC>
	<brief_summary>To assess the safety and efficacy of PMI-150 (Intranasal Ketamine) as an analgesic for the treatment of breakthrough pain in cancer patients.</brief_summary>
	<brief_title>Safety and Efficacy of PMI-150 (Intranasal Ketamine) for the Treatment of Breakthrough Pain in Cancer Patients</brief_title>
	<detailed_description>The primary objective is to evaluate the safety and efficacy following the administration of intranasal ketamine in providing pain relief as compared to placebo.</detailed_description>
	<mesh_term>Breakthrough Pain</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>at least 18 years of age Patients requiring aroundtheclock opioids for pain due to cancer and with a history of experiencing episodes of breakthrough pain under 18 years noncancer pain allergy to ketamine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>breakthrough</keyword>
	<keyword>pain</keyword>
	<keyword>cancer</keyword>
</DOC>